Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARCUS BIOSCIENCES, INC.

(RCUS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Arcus Biosciences : Chief Medical Officer Resigns to Join Gilead's Oncology Team

07/20/2021 | 04:33am EDT


© MT Newswires 2021
All news about ARCUS BIOSCIENCES, INC.
08:31aARCUS BIOSCIENCES : Thinking about buying stock in Corvus Pharmaceuticals, AbCel..
PR
09/09ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
09/01ARCUS BIOSCIENCES : to Participate at Upcoming Investor Conferences
BU
08/24ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
08/11ARCUS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08/11Arcus Biosciences, Inc. Announces Board Changes
CI
08/10ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
08/06ARCUS BIOSCIENCES : SVB Leerink Adjusts Price Target on Arcus Biosciences to $68..
MT
08/05ARCUS BIOSCIENCES : Earnings Flash (RCUS) ARCUS BIOSCIENCES Reports Q2 Revenue $..
MT
08/05ARCUS BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
More news
Analyst Recommendations on ARCUS BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 39,3 M - -
Net income 2021 -300 M - -
Net cash 2021 555 M - -
P/E ratio 2021 -7,70x
Yield 2021 -
Capitalization 2 598 M 2 598 M -
EV / Sales 2021 52,0x
EV / Sales 2022 17,0x
Nbr of Employees 236
Free-Float 63,2%
Chart ARCUS BIOSCIENCES, INC.
Duration : Period :
Arcus Biosciences, Inc. Technical Analysis Chart | RCUS | US03969F1093 | MarketScreener
Technical analysis trends ARCUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 33,03 $
Average target price 53,90 $
Spread / Average Target 63,2%
EPS Revisions
Managers and Directors
Terry J. Rosen Chairman & Chief Executive Officer
Juan Carlos Jaen President & Director
Robert C. Goeltz Chief Financial & Accounting Officer
Steve Young Senior VP-Technology & Quantitative Biology
Kartik Krishnan Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ARCUS BIOSCIENCES, INC.27.23%2 358
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.19.23%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.28%209 456